Overview
Opportunities with Novel Therapies to Treat the Entire Spectrum of Schizophrenia Symptoms
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
Available antipsychotic therapies for schizophrenia are effective in treating positive symptoms of schizophrenia yet significant unmet needs remain, including therapies that (1) are more effective in reducing negative and cognitive symptoms of schizophrenia; 2) have improved tolerability and adherence rates; and (3) that are effective in treating refractory schizophrenia. Fortunately, the schizophrenia treatment landscape is poised to change dramatically, offering new opportunities for patients. Designed with your questions in mind, this digital FAQ index offers succinct and relevant information for clinicians on an array of questions including:
• What are some of the emerging therapies for schizophrenia, and how do they differ from current treatment options?
• Which emerging therapies address negative and/or cognitive symptoms?
• What is the latest clinical trial evidence around novel therapies?
• What are the clinical implications of the latest evidence?
Start the activity to find out the answers to these questions and more!
• What are some of the emerging therapies for schizophrenia, and how do they differ from current treatment options?
• Which emerging therapies address negative and/or cognitive symptoms?
• What is the latest clinical trial evidence around novel therapies?
• What are the clinical implications of the latest evidence?
Start the activity to find out the answers to these questions and more!
This activity is intended for psychiatrists, neurologists, primary care/internal medicine physicians, psychologists, and other members of the multidisciplinary treatment team.
The pharmacologic management of schizophrenia has long revolved around antagonism of the D2 family of dopamine receptors. Although current therapies are effective for alleviating the positive symptoms of schizophrenia, they are relatively ineffective for the reduction of negative and cognitive symptoms. In addition, their side effects can be particularly bothersome and contribute to poor treatment adherence. With significant gaps in treatment within the current therapeutic landscape, new medications with novel targets are currently being developed with the goals of improved efficacy across the spectrum of schizophrenia symptoms and an improved safety profile. Because new therapies with novel mechanisms of action are likely to become part of the treatment armamentarium in the near future, physicians require education on these emerging therapies to be prepared to incorporate them within clinical practice to better individualize care and improve patient outcomes.
Upon completion of this activity, learners will be able to:
• Outline existing therapeutic barriers and unmet clinical needs in schizophrenia
• Evaluate the rationale for novel therapeutic targets for the treatment of schizophrenia
• Discuss clinical trial results demonstrating efficacy and differentiated side effect profiles of novel muscarinic receptor activators for the treatment of schizophrenia
• Outline existing therapeutic barriers and unmet clinical needs in schizophrenia
• Evaluate the rationale for novel therapeutic targets for the treatment of schizophrenia
• Discuss clinical trial results demonstrating efficacy and differentiated side effect profiles of novel muscarinic receptor activators for the treatment of schizophrenia
Provided by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Bristol Myers Squibb.
Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Professor of Psychiatric Neuroscience, Institute of Behavioral Science
Feinstein Institutes for Medical Research
New York, USA
Professor and Chair, Department of Child and Adolescent Psychiatry
Charité University Medicine
Berline, Germany
Professor of Psychiatry and Molecular Medicine
The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Professor of Psychiatric Neuroscience, Institute of Behavioral Science
Feinstein Institutes for Medical Research
New York, USA
Professor and Chair, Department of Child and Adolescent Psychiatry
Charité University Medicine
Berline, Germany
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Christoph U. Correll, MD
Sources of Funding for Research: Boehringer-Ingelheim, Janssen and Takeda
Consulting/Advisor Agreements: AbbVie, Acadia, Adock Ingram, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Eli Lilly, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Sage, Saladax, Sanofi, Seqirus, SK Life Science, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Terran, Tolmar, Vertex, Viatris and Xenon Pharmaceuticals
DSMB Membership: Boehringer-Ingelheim, Janssen and Takeda
Royalties: UpToDate
Stock Options: Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax, Quantic, Terran.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: amisulpride, pimozide, zotepine, zuclopenthixol, sulpiride, clopenthixol, sertindole, perazine, iclepertin, roluperidone, ulotaront, and emraclidine are not FDA-approved for the treatment of schizophrenia
This activity will take approximately 60 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
